Finance

Lists
CNSY:NASDAQ
Cerenome, Inc.
$3.05
-1.61%
(-0.050) 1D
Aug 28, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CNSY...
Open
$3.13
High
$3.19
Low
$3.00
Mkt. cap
23.15M
Avg. vol.
51.60K
Volume
35.20K
52-wk high
$4.16
52-wk low
$2.92
EPS
-$4.42
Beta
1.43
Shares outstanding
7.59M
No. of employees
28
Open
$3.13
High
$3.19
Low
$3.00
Mkt. cap
23.15M
Avg. vol.
51.60K
Volume
35.20K
52-wk high
$4.16
52-wk low
$2.92
EPS
-$4.42
Beta
1.43
Shares outstanding
7.59M
No. of employees
28
News stories
From web sources and news partners
Profile
Cerenome, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®. Wikipedia
About Cerenome, Inc.
CEO-
Employees28
Founded1996
Headquarters-
SectorBiotechnology
Websitecerenome.com
Analyst ratings
Based on 2 analysts giving stock ratings to CNSY in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for CNSY in the last 3 months.
Highest
Current $3.05
$57.00 (+1,768.85%)
Average
$53.50 (+1,654.10%)
Lowest
$50.00 (+1,539.34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Chad Messer
Lake Street
Buy
Reiterated
$50.00
+1,539.3%
07/01/2026
Edward Woo
Ascendiant
Buy
Maintained
$57.00
+1,768.9%
06/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.40M
1.37M
1.03M
411.00K
Cost of goods sold
2.44M
2.94M
2.86M
-
Cost of revenue
2.44M
2.94M
2.86M
-
Research and development expenses
-
-
-
4.26M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.44M
4.17M
5.28M
5.20M
Operating expense
3.44M
4.17M
5.28M
9.47M
Total operating expenses
5.88M
7.11M
8.15M
9.47M
Operating income
-4.48M
-5.74M
-7.12M
-9.06M
Other non operating income
-
-
-
-
EBT including unusual items
-4.42M
-5.71M
-6.95M
-9.01M
EBT excluding unusual items
-4.42M
-5.71M
-6.95M
-9.01M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-4.42M
-5.71M
-6.95M
-9.01M
Net profit margin
-316.61%
-417.92%
-675.68%
-2,191.24%
Earnings per share
-1.00
-
-1.05
-1.31
Interest and investment income
59.00K
29.00K
190.00K
56.00K
Interest expense
-
-
-17.00K
-5.00K
Net interest expenses
59.00K
29.00K
173.00K
51.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-4.40M
-5.60M
-7.02M
-8.92M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps